In last trading session, BIOLASE, Inc. (NASDAQ:BIOL) saw 3,658,751 shares changing hands with its beta currently measuring 1.96. Company’s recent per share price level of $0.29 trading at $0.01 or 2.8% at ring of the bell on the day assigns it a market valuation of $26.64 Million. That closing price of BIOL’s stock is at a discount of -231.03% from its 52-week high price of $0.96 and is indicating a premium of 27.59% from its 52-week low price of $0.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.01 Million shares which gives us an average trading volume of 2.25 Million if we extend that period to 3-months.
For BIOLASE, Inc. (BIOL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.7. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.04 in the current quarter.
BIOLASE, Inc. (NASDAQ:BIOL) trade information
Upright in the green today for gaining 2.8%, in the last five days BIOL remained trading in the green while hitting it’s week-highest on Thursday, Nov 19 when the stock touched $0.2966 price level, adding 3.44% to its value on the day. BIOLASE, Inc.’s shares saw a change of -48.18% in year-to-date performance and have moved -7.61% in past 5-day. BIOLASE, Inc. (NASDAQ:BIOL) showed a performance of -5.51% in past 30-days. Number of shares sold short was 494.16 Million shares which calculate 219.63 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $1.41 to the stock, which implies a rise of 386.21% to its current value. Analysts have been projecting $1 as a low price target for the stock while placing it at a high target of $2. It follows that stock’s current price would jump +589.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of 244.83% for stock’s current value.
BIOLASE, Inc. (BIOL) estimates and forecasts
Statistics highlight that BIOLASE, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -42.02% of value to its shares in past 6 months, showing an annual growth rate of -67.53% while that of industry is -0.3. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 20% in the current quarter and calculating 78.9% increase in the next quarter. This year revenue growth is estimated to drop -42.7% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $7.43 Million for the same. And 4 analysts are in estimates of company making revenue of $6.96 Million in the next quarter that will end in March 01, 2021. Company posted $10.18 Million and $4.78 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -27% while estimating it to be 45.5% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.2% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 28.4% while estimates for its earnings growth in next 5 years are of 20%
BIOLASE, Inc. (NASDAQ:BIOL)’s Major holders
Insiders are in possession of 10.63% of company’s total shares while institution are holding 11.79% percent of that, with stock having share float percentage of 13.19%. Investors also watch the number of corporate investors in a company very closely, which is 38 institutions for BIOLASE, Inc. that are currently holding shares of the company. Oracle Investment Management Inc is the top institutional holder at BIOL for having 1.74 Million shares of worth $478.43 Thousand. And as of September 29, 2020, it was holding 1.87% of the company’s outstanding shares.
The second largest institutional holder is Perkins Capital Management, Inc., which was holding about 1.11 Million shares on September 29, 2020. The number of shares represents firm’s hold over 1.19% of outstanding shares, having a total worth of $305.64 Thousand.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 815191 shares of worth $377.43 Thousand or 0.88% of the total outstanding shares. The later fund manager was in possession of 184.51 Thousand shares on June 29, 2020, making its stake of worth around $85.43 Thousand in the company or a holder of 0.2% of company’s stock.